• 基本信息
    导师姓名： 王理伟 学科代码： 100214
    性别： 男 学科名称： 肿瘤学
    培养单位： 附属仁济医院 三级学科
    导师类型： 博士生导师 专业领域名称： 肿瘤学 专业学位
    联系方式： 邮箱：liwewang@shsmu.edu.cn或 lwwang2013@163.com 专业领域代码： 105121
    邮编： 200127 邮箱地址： yzwlw@yahoo.com
  • 研究方向 (点击浏览详细信息)
  • 社会任职
     
    临床肿瘤学，二级教授、主任医师、博士生导师。现为上海交通大学医学院附属仁济医院肿瘤科主任；中华医学会肿瘤学分会委员兼胰腺肿瘤学组组长；仁济医院MDT专家委员会主任委员；中国研究型医院学会胰腺疾病专业委员会副主任委员；上海交通大学胰腺癌诊治中心主任；上海市抗癌协会副理事长兼疑难肿瘤专委会主任委员；中国临床肿瘤学会（CSCO）理事；上海医学会肿瘤专科分会副主任委员；中国临床肿瘤学会胰腺癌专家委员会主任委员；上海市领军人才、上海市优秀学科带头人；主要从事消化系统肿瘤临床诊治和转化研究; 2001至2004年美国加州大学洛杉矶分校(UCLA)和MD Anderson肿瘤中心访问研究; 2012年入选上海市优秀学科带头人; 2017年入选上海领军人才; 主持制定了我国首个《胰腺癌综合诊治中国专家共识》和中国临床肿瘤学会首个《CSCO胰腺癌诊疗指南》; 主持包括自然基金重大研究计划在内的 5 项国家自然基金项目、2项重大新药创制项目和10 多项各类基金项目; 现为《Journal of Pancreatology》副主编，《Cancer Research》、《JHO》、《肿瘤》、《临床肿瘤学》 等杂志编委，发表SCI论文100余篇，他引1000余次 。
  • 科研项目
    项目编号项目名称课题来源起止年月批准经费承担职责
    SHDC2020CR1035B抗PD-1抗体（艾瑞卡）联合紫杉醇（白蛋白结合型）和吉西他滨对比紫杉醇（白蛋白结合型）和吉西他滨一线治疗转移性胰腺癌有效性与安全性的前瞻性、随机双盲、多中心临床研究上海市临床三年行动计划重大临床研究项目一类资助 2020-10~2022-09 715万元  课题负责人
    81874048Stat5调控NLRP3诱导细胞焦亡招募MDSC介导胰腺炎癌转化的机制国家自然科学基金面上项目 2019-01~2022-12 58万元  课题负责人
    2019CXJQ03肿瘤精准医学临床实践中的关键分子检测技术研发和转化应用上海市卫健委 2019-01~2023-12 410万元  子课题负责人
    /上海市临床重点专科建设项目（腾飞计划）-肿瘤科上海市卫健委 2018-11~2020-12 500万元  课题负责人
    2018ZHYL0223整合临床信息与组学信息的智能精准医学临床决策支持系统的研究与应用上海市重点项目（卫生计生委智慧医疗专项研究项目） 2018-07~2021-06 17.55万元  子课题负责人
    2018ZX09711001-007-010K-001治疗三线及以上晚期胰腺癌患者的多中心Ⅱ/Ⅲ期临床研究重大新药创制科技重大专项 2018-01~2020-12 318万元  课题负责人
    17领军上海市领军人才项目上海市人社局 2018-01~2020-12 50万元  课题负责人
    81572315Sp1调控的炎性介质诱导巨噬细胞M2极化介导胰腺癌耐药的机制国家自然科学基金面上项目 2016-01~2019-12 45万元  课题负责人
    SHDC12014128免疫细胞联合吉西他滨治疗晚期胰腺癌的疗效评估体系和规范的建立上海市市级医院新兴前沿技术联合攻关项目 2014-01~2017-12 50万元  课题负责人
    91229117胰腺炎恶性转化基因调控网络中转录因子Sp1作为关键节点的调控机制国家自然科学基金重大研究计划 2013-01~2015-12 90万元  课题负责人
  • 学术论文
    作者论文标题期刊名出版年卷期页码
    Ge W, Yue M, Lin R, Zhou T, Xu H, Wang Y, Mao T, Li S, Wu X, Zhang X, Wang Y, Ma J, Wang Y, Xue S, Shentu D, Cui J,  PLA2G2A+ cancer-associated fibroblasts mediate pancreatic cancer immune escape via impeding antitumor immune response of CD8+ cytotoxic T cells  Cancer Letters  2023  558:216095 
    Li S, Yue M, Xu H, Zhang X, Mao T, Quan M, Ma J, Wang Y, Ge W, Wang Y, Xue S, Shentu D, Cui J,  Chemotherapeutic drugs-induced pyroptosis mediated by gasdermin E promotes the progression and chemoresistance of pancreatic cancer  Cancer Letter  2023  564:216206 
    Yu Wang # , Yiyi Liang #, Haiyan Xu #, Xiao Zhang, Tiebo Mao, Jiujie Cui, Jiayu Yao, Yongchao Wang, Feng Jiao, Xiuying Xiao, Jiong Hu, Qing Xia, Xiaofei Zhang, Xujun Wang, Yongwei Sun, Deliang Fu, Lei Shen, Xiaojiang Xu*, Jing Xue*,  Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response  cell discovery  2021  7:36 
    Ming Quan#,Zhiqin Chen#,Feng Jiao,Xiuying Xiao,Qing Xia,Jingde Chen,Qian Chao,Yandong Li,Yong Gao, Haiyan Yang*,Liwei Wang*,  Lysine Demethylase 2 (KDM2B) Regulates Hippo Pathway via MOB1 to Promote Pancreatic Ductal Adenocarcinoma (PDAC) Progression  J Exp Clin Cancer Res  2020  39（1） 
    Zhuo M#, Yuan C#, Han T#, Hu H, Cui J, Jiao F*,  JQ1 effectively inhibits vasculogenic mimicry of pancreatic ductal adenocarcinoma cells via the ERK1/2-MMP-2/9 signaling pathway both in vitro and in vivo  Am J Transl Res  2019  11: 1030-1039 
    Cui J, Zhou Z, Yang H, Jiao F, Li N, Gao Y,, Chen J, Quan M.  MST1 Suppresses Pancreatic Cancer Progression via ROS-induced Pyroptosis  Mol Cancer Res  2019  17(6):1316-1325 
    Han T, Zhuo M, Hu H, Jiao F,  Synergistic effects of the combination of 5-AzaCdR and suberoylanilide hydroxamic acid on the anticancer property of pancreatic cancer  Oncol Rep  2018  39(1), 264-270 
    Wang Y, Xiao XY, Wang TU, Li L, Zhu Y, Xu HY, Chu YN, Jiao F, Cui JJ,  A Survival Model in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma  J Cancer  2018  9(7):1301–7.  
    Zhuo Meng., Yuan Cuncun., Han Ting., Cui Jiujie.,, Wang Liwei.   A novel feedback loop between high MALAT-1 and low miR-200c-3p promotes cell migration and invasion in pancreatic ductal adenocarcinoma and is predictive of poor prognosis  BMC Cancer  2018  18, 1032 
    Yu Wang, Jiacheng Lin, Jiujie Cui, Ting Han, Feng Jiao, Zhuo Meng,  Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancreatic cancer   Oncotarget  2018  8(6): 9354-9365 
    Han T, Zhuo M, Hu H, Jiao F,  Synergistic effects of the combination of 5-AzaCdR and suberoylanilide hydroxamic acid on the anticancer property of pancreatic cancer  ONCOL REP  2018  39:264-270 
    Hu H, Han T, Zhuo M, Wu LL, Yuan C, Wu L, Lei W, Jiao F,  Elevated COX-2 Expression Promotes Angiogenesis Through EGFR/p38-MAPK/Sp1-Dependent Signalling in Pancreatic Cancer  Sci Rep  2017  7:470. 
    Hai Hu, Hong Li, Feng Jiao, Ting Han, Meng Zhuo, Jiujie Cui1, Yixue Li,  Association of a novel point mutation in MSH2 gene with familial multiple primary cancers   Journal of Hematology & Oncology  2017  10(1):158-158 
    Han T, Hu H, Zhuo M, Wang L, Cui JJ, Jiao F,  Long non-coding RNA: An emerging paradigm of pancreatic cancer.  Curr Mol Med.  2016  16:702-709. 
    Cui J, Quan M, Jiang W, Hu H, Jiao F, Li N, Jin Z, Wang L, Wang Y,  Suppressed expression of LDHB promotes pancreatic cancer progression via inducing glycolytic phenotype.   Med Oncol   2015  32:589. 
    Song W, Li Q, Wang L,  Modulation of FoxO1 expression by miR-21 to promote growth of pancreatic ductal adenocarcinoma.   Cell Physiol Biochem  2015  35(1):184-190 
    Xue P, Zhu L, Wan Z, Huang W, Li N, Chen D, Hu J, Yang H,  A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy.  J Cancer Res Clin Oncol  2015  :1-8 
    Jiao F, Hu H, Han T, Yuan C, Wang L, Jin Z, Guo Z,  Long Noncoding RNA MALAT-1 Enhances Stem Cell-Like Phenotypes in Pancreatic Cancer Cells  Int J Mol Sci  2015  16:6677-93. 
    Song W, Li Q, Wang L, Huang W,  FoxO1-negative cells are cancer stem-like cells in pancreatic ductal adenocarcinoma.   Sci Rep  2015  ,5:10081 
    Weihua Jiang, Ziliang Jin, Fei Zhou, Jiujie Cui, Lei Wang,  High co-expression of sp1 and her-2 is correlated with poor prognosis of gastric cancer patients.   Surgical Oncology  2015  [Epub ahead of print] 
    Hu H, Jiao F, Han T,  Functional significance of macrophages in pancreatic cancer biology.  Tumour Biol  2015  2015 Sep 28. [Epub ahead of print] 
    Jiang W, Zhou F, Li N, Li Q,  FOXM1-LDHA signaling promoted gastric cancer glycolytic phenotype and progression.  Int J Clin Exp Pathol,  2015  8(6):6756-6763,  
    Jiao F, Hu H, Yuan C, Jin Z, Guo Z,, Wang L  Histone deacetylase 3 promotes pancreatic cancer cell proliferation, invasion and increases drug-resistance through histone modification of P27, P53 and Bax.  Int J Oncol   2014  45:1523-30. 
    Jiao F, Hu H, Yuan C, Wang L, Jiang W, Jin Z, Guo Z,  Elevated expression level of long noncoding RNA MALAT-1 facilitates cell growth, migration and invasion in pancreatic cancer.  Oncol Rep  2014  32:2485-92. 
    Cui J, Jiang W, Wang S,, Xie K  Role of Wnt/β-catenin Signaling in Drug Resistance of Pancreatic Cancer  Curr Pharm Des  2012  18(17):2464-71 
    Jiang W, Cui J, Xie D,  Sp/KLF Family and Tumor Angiogenesis in Pancreatic Cancer  Curr Pharm Des  2012  18(17):2420-31 
    Zhou F, Li N, Jiang W, Hua Z, Xia L, Wei Q,  Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial  World J Surg Oncol  2012  10(1):274-8 
    Gao Y, Jia Z, Kong X, Li Q, Chang DZ, Wei D,Le X,Huang S,, Xie K  Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis  Cancer Res  2011  71(15):5182-93 
    Wei D,,（王理伟）. Kanai M, Jia Z, Le X, Li Q, Wang H, Xie K  KLF4α up-regulation promotes cell cycle progression and reduces survival time of patients with pancreatic cancer  Gastroenterology  2010  139(6):2135-45 
    Jia Z, Gao Y,, Li Q, Zhang J, Le X, Wei D, Yao JC, Chang DZ, Huang S, Xie K.  Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity  Cancer Res  2010  70(3):1111-1119 
    , Xiaohong Guan, Jun Zhang Zhiliang Jia, Daoyan Wei, Qiang Li, James Yao and Keping Xie  Targeted inhibition of Sp1-mediated transcription for antiangiogenic therapy of metastatic human gastric cancer in orthotopic nude mouse models  International Journal of Oncology  2008  33(6):161-167 
    Yuan P,,（王理伟）, Wei D, Zhang J, Jia Z, Li Q, Le X, Wang H, Yao J, Xie K.  Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer.  Cancer  2007  110(12):2682-2690 
    ,Guan X, Gong W, Yao J, Peng Z, Wei D, Wu TT, Huang S, Xie K  Altered Expression of Transcription Factor Sp1 Critically Impacts the Angiogenic Phenotype of Human Gastric Cancer.  Clin Exp Metastasis  2005  22（3）:205-213 
    , Wei D, Huang S, Peng Z, Le X, Wu T T, Yao J, Ajani J, Xie K.  Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer.  Clin Cancer Res,  2003  9(17):6371-6380,